Fig. 1: The expression of EZH2 in different types of breast cancer patients. | Cell Death Discovery

Fig. 1: The expression of EZH2 in different types of breast cancer patients.

From: Capsanthin inhibits migration and reduces N-linked glycosylation of PD-L1 via the EZH2-PD-L1 axis in triple-negative breast cancer brain metastasis

Fig. 1

A Box plots showing the transcript per million (TPM) values of EZH2 in normal breast tissue (n = 114), luminal breast cancer (n = 566), HER2 positive breast cancer (n = 37), and triple-negative breast cancer (TNBC, n = 116) from TCGA samples. EZH2 expression is significantly higher in luminal, HER2 positive, and TNBC samples compared to normal breast tissue. B Box plots displaying EZH2 expression in different subtypes of TNBC, including basal-like 1 (BL1, n = 16), basal-like 2 (BL2, n = 10), immunomodulatory (IM, n = 9), mesenchymal (M, n = 5), mesenchymal stem-like (MSL, n = 5), luminal androgen receptor (LAR, n = 6), and unspecified (UNS, n = 27). EZH2 expression is significantly higher in these subtypes compared to normal breast tissue. C Kaplan–Meier survival curves illustrating the relationship between EZH2 expression and overall survival in breast cancer patients. Left: High EZH2 expression is associated with poorer survival in all breast cancer patients (HR = 1.27, 95% CI = 1.05–1.53, p = 0.013). Middle: There is no significant difference in survival between high and low EZH2 expression in TNBC patients (HR = 0.79, 95% CI = 0.55–1.14, p = 0.21). Right: High EZH2 expression correlates with significantly poorer survival in grade 3 TNBC patients (HR = 1.93, 95% CI = 1.16–3.21, p = 0.0097) (*p < 0.05, **p < 0.01, ***p < 0.001).

Back to article page